MedTrace Logo

Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis

NCT06863701 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-04-03

No results posted yet for this study

Summary

Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the Fixed-Dose Combination of Etoricoxib/Betamethasone Versus Etoricoxib in Patients With Acute Gouty Arthritis

Conditions

  • Gout Arthritis
  • Gout Attack

Interventions

DRUG

Etoricoxib + Betamethasone fixed dose

One tablet of 90 mg / 0.25 mg a day

DRUG

Etoricoxib fixed dose

One pill of 90 mg a day

Sponsors & Collaborators

  • Laboratorios Silanes S.A. de C.V.

    lead INDUSTRY

Principal Investigators

  • Rafael Lanuza-Ramirez, MD · Consultorio Médico "Dr. Rodrigo Suárez Otero"

  • Rodrigo Suarez-Otero, MD · SMIQ, S. De. R.L. de C.V. (Grupo Cien y ético de Querétaro)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-27
Primary Completion
2026-12-31
Completion
2027-01-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06863701 on ClinicalTrials.gov